StockData
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. (ALGS) stock

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)

Close on Nov 17, 2026Market cap $16.99MP/E –Yield –

Aligos Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aligos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $3.74M, up 19.4% year over year. For fiscal 2025 it was $2.19M, down 39.5% from the year before. The highest annual figure on record is $6.19M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.19M-39.5%
FY2024Dec 31, 2024$3.61M-41.7%
FY2023Dec 31, 2023$6.19M–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$2.83M+810.0%
Q4 FY2025Dec 31, 2025$169.00K-72.1%
Q3 FY2025Sep 30, 2025$741.00K-40.7%
Q2 FY2025Jun 30, 2025$965.00K-9.0%
Q1 FY2025Mar 31, 2025$311.00K-55.2%
Q4 FY2024Dec 31, 2024$606.00K-9.8%
Q3 FY2024Sep 30, 2024$1.25M+15.2%
Q2 FY2024Jun 30, 2024$1.06M-75.3%
Q1 FY2024Mar 31, 2024$694.00K+395.7%
Q4 FY2023Dec 31, 2023$672.00K–
Q3 FY2023Sep 30, 2023$1.09M–
Q2 FY2023Jun 30, 2023$4.29M–
Q1 FY2023Mar 31, 2023$140.00K–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–

More Aligos Therapeutics figures

See a number that looks wrong?